The iconic rise of Viagra has consistently remained a benchmark of pharmaceutical success, however its future within the broader industry now raises questions about long-term yields . Copycat versions are diminishing exclusivity , leading to concerns that supporting companies significantly dependent to Viagra's once-dominant standing could be a dan